Zacks: Brokerages Set $5.50 Target Price for AEterna Zentaris Inc. (AEZS)

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports.

Brokers have set a 1-year consensus target price of $5.50 for the company and are expecting that the company will post $0.04 EPS for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 50 out of 255 based on the ratings given to its competitors.

A number of research firms recently issued reports on AEZS. ValuEngine upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd. HC Wainwright reissued a “buy” rating on shares of AEterna Zentaris in a research report on Thursday, January 17th. Finally, Zacks Investment Research raised shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Monday, March 18th.

AEZS traded down $0.06 during midday trading on Tuesday, reaching $4.25. 139,195 shares of the company’s stock were exchanged, compared to its average volume of 339,237. The stock has a market cap of $69.87 million, a price-to-earnings ratio of 17.00 and a beta of 1.25. AEterna Zentaris has a one year low of $1.29 and a one year high of $5.57.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings data on Tuesday, March 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.12). The firm had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.25 million. AEterna Zentaris had a return on equity of 55.49% and a net margin of 15.67%. On average, analysts expect that AEterna Zentaris will post 2.25 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of AEZS. Jane Street Group LLC purchased a new position in shares of AEterna Zentaris in the fourth quarter worth about $30,000. O Shaughnessy Asset Management LLC purchased a new position in shares of AEterna Zentaris in the fourth quarter worth about $66,000. Virtu Financial LLC purchased a new position in shares of AEterna Zentaris in the third quarter worth about $101,000. Finally, Acadian Asset Management LLC increased its stake in shares of AEterna Zentaris by 27.2% in the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 9,640 shares in the last quarter. Hedge funds and other institutional investors own 15.29% of the company’s stock.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Featured Story: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.